首页> 美国卫生研究院文献>Medicina >CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction
【2h】

CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction

机译:CHA2DS2-VASc评分是急性ST段抬高型心肌梗死患者主PCI后亚最佳再灌注和短期死亡率的独立预测因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and objectives: We aimed to demonstrate the clinical utility of CHA2DS2-VASc score in risk assessment of patients with STEMI regarding adverse clinical outcomes particularly no-reflow phenomenon. Materials and Methods: We designed a retrospective cohort study using the data of Tehran Heart Center registry for acute coronary syndrome. The study included 1331 consecutive patients with STEMI who underwent primary angioplasty. Patients were divided into two groups according to low and high CHA2DS2-VASc score. Angiographic results of reperfusion were inspected to evaluate the association of high CHA2DS2-VASc score and the likelihood of suboptimal TIMI flow. The secondary endpoint of the study was short-term in-hospital mortality of all cause. Results: The present study confirmed that CHA2DS2-VASc model enables us to determine the risk of no-reflow and all-cause in-hospital mortality independently. Odds ratios were 1.59 (1.30–2.25) and 1.60 (1.17–2.19), respectively. Moreover, BMI, high thrombus grade, and cardiogenic shock were predictors of failed reperfusion (odds were 1.07 (1.01–1.35), 1.59 (1.28–1.76), and 8.65 (3.76–24.46), respectively). We showed that using a cut off value of ≥ two in CHA2DS2-VASc model provides a sensitivity of 69.7% and specificity of 64.4% for discrimination of increased mortality hazards. Area under the curve: 0.72 with 95% CI (0.62–0.81). Conclusions: Calculation of CHA2DS2-VASc score applied as a simple risk stratification tool before primary PCI affords great predictive power. Furthermore, incremental values are obtained by using both CHA2DS2-VASc and no-reflow regarding mortality risk assessment.
机译:背景与目的:我们旨在证明CHA2DS2-VASc评分在STEMI患者不良临床预后尤其是无复流现象风险评估中的临床应用。材料和方法:我们使用德黑兰心脏中心登记处的数据对急性冠脉综合征进行了一项回顾性队列研究。该研究包括1331例接受原发性血管成形术的连续性STEMI患者。根据CHA2DS2-VASc评分的高低将患者分为两组。检查了再灌注的血管造影结果,以评估CHA2DS2-VASc高评分与TIMI血流欠佳的可能性之间的关系。研究的次要终点是所有原因的短期住院死亡率。结果:本研究证实,CHA2DS2-VASc模型使我们能够独立确定无复流和全因医院内死亡的风险。赔率分别为1.59(1.30–2.25)和1.60(1.17–2.19)。此外,BMI,高血栓等级和心源性休克是再灌注失败的预测指标(分别为1.07(1.01–1.35),1.59(1.28–1.76)和8.65(3.76–24.46))。我们显示,在CHA2DS2-VASc模型中使用大于或等于2的临界值可以区分出增加的死亡危险,灵敏度为69.7%,特异性为64.4%。曲线下面积:0.72,95%CI(0.62-0.81)。结论:CHA2DS2-VASc分数的计算被用作简单的风险分层工具,而初级PCI则提供了强大的预测能力。此外,通过使用CHA2DS2-VASc和无复流来获得关于死亡风险评估的增量值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号